Boston Scientific Corp. has agreed to pay $119 million to settle nearly 3,000 cases and claims over its transvaginal surgical mesh products, the company disclosed Tuesday in a filing with the Securities and Exchange Commission.
Marlborough, Mass.-based Boston Scientific said in the SEC filing it reached the tentative settlement agreement “solely by way of compromise” and the agreement “does not constitute an admission or concession by the company of any liability or wrongdoing.”
Patients have alleged they were injured by the mesh products—which are meant to treat stress urinary incontinence and pelvic organ prolapse. As of February, more than 25,000 product liability cases or claims regarding the mesh products had been made against the company, according to Boston Scientific filings.
Boston Scientific spokesperson Kelly Leadem said in an e-mail Tuesday that when it comes to those other cases and claims, the company continues to look at all of its options.
"If there are opportunities to settle cases at reasonable terms in the future, then we will consider settling," Leadem wrote. "Otherwise, we will continue to contest these claims vigorously."
The settlement announced Tuesday includes, among the 2,970 cases and claims it resolves, a case in the District Court of Dallas County in Texas for which there has been a judgment of about $35 million that is subject to appeal.